TBC1D1 and melanoma: Analysis of the TIGER database of patients receiving anti-PD-1 immunotherapy for melanoma revealed that TBC1D1 impedes the effectiveness of the treatment, leading to suboptimal patient survival rates (Supplementary Figure S5B).